Table 5.
Immunohistochemistry and in situ hybridization results
| Case | Diagnosis | AKAP13 | COL1A1 | COL3A1 | COL4A1 | COL6A2 | CXCR7 | HSPG2 | ITGA5 | MMP14 | PV1 | PXDN | SOX4 | TEM1 | vWF |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Normal | +/− | +/− | +/− | + | −− | −− | +/− | +/− | +/− | −− | +/− | −− | − | + |
| 2 | Normal | −− | +/− | +/− | + | −− | −− | +/− | +/− | −− | −− | −− | −− | − | + |
| 3 | Normal | −− | −− | −− | + | −− | −− | −− | −− | −− | −− | −− | −− | − | N/D |
| 4 | Normal | −− | + | + | + | +/− | + | + | + | + | +/− | −− | +/− | − | + |
| 5 | Normal | −− | + | +/− | + | +/− | +/− | +/− | +/− | +/− | −− | +/− | + | +/− | + |
| 6 | Normal | −− | −− | +/− | + | −− | −− | −− | −− | −− | −− | +/− | +/− | + | + |
| 7 | Normal | +/− | −− | −− | + | −− | +/− | −− | −− | −− | +/− | +/− | −− | +/− | + |
| 8 | PA | +/− | ++ | +++ | +++ | ++ | ++ | ++ | ++ | + | +/− | + | ++ | +++ | +++ |
| 9 | PA | + | + | + | + | +/− | −− | + | −− | +/− | + | + | + | + | ++ |
| 10 | PA | +/− | +/− | ++ | ++ | ++ | + | + | + | +/− | + | +/− | + | + | ++ |
| 11 | PA | +/− | −− | +/− | + | −− | −− | −− | +/− | −− | +/− | +/− | +/− | − | + |
| 12 | Met | + | ++ | +++ | +++ | +++ | +++ | ++ | +++ | +/− | +++ | ++ | ++ | +++ | +++ |
| 13 | Met | −− | ++ | +++ | +++ | +++ | +++ | + | +++ | −− | ++ | −− | + | + | +++ |
| 14 | Met | +/− | ++ | ++ | ++ | + | + | + | + | + | + | +/− | + | ++ | ++ |
| 15 | Met | +/− | + | ++ | ++ | +/− | +/− | ++ | + | +/− | +/− | +/− | + | + | ++ |
| 16 | Met | +++ | + | +++ | +++ | +++ | +/− | ++ | ++ | + | +++ | +++ | + | +++ | ++ |
| 17 | Met | ++ | +/− | ++ | ++ | ++ | −− | + | + | + | + | ++ | ++ | ++ | ++ |
| 18 | Met | +/− | ++ | ++ | +++ | ++ | +/− | −− | +/− | ++ | +/− | −− | + | + | ++ |
| 19 | GBM | +/− | + | + | + | + | −− | −− | + | +/− | +/− | + | + | + | + |
| 20 | GBM | −− | −− | +/− | + | −− | +/− | −− | +/− | −− | −− | + | +/− | ++ | ++ |
| 21 | GBM | −− | +/− | + | ++ | + | ++ | +/− | + | +/− | +/− | ++ | + | +/++ | +++ |
| 22 | GBM | +/− | +/− | + | + | +/− | −− | +/− | +/− | +/− | +/− | +/− | +/− | + | +/− |
| 23 | GBM | +/− | −− | ++ | +++ | +/− | +/− | + | ++ | +/− | + | ++ | ++ | +++ | + |
| 24 | GBM | +/− | −− | +/− | + | −− | +/− | +/− | +/− | −− | +/− | +/− | +/− | ++ | +++ |
| 25 | GBM | N/D | −− | + | + | +/− | −− | −− | +/− | ++ | N/D | +/− | +/− | + | + |
| 26 | GBM | + | +/− | ++ | ++ | + | + | +/− | + | +/− | +/− | +++ | + | +++ | ++ |
| 27 | GBM | +/− | +/− | ++ | + | +/− | −− | −− | +/− | +/− | −− | + | +/− | +++ | +++ |
| Sig. | − | M | M | M | M | − | M,G | M | M | − | G | M,G | − |
Scores:− −, 0% of vessels; +/−, occasional vessel; +, 10% of vessels; ++, 50% of vessels; +++, 100% of vessels. PXDN, PV1, and AKAP13 were measured by in situ hybridization and all others were measured by immunohistochemistry. CD31 was used as a control to ensure that viable protein and mRNA was present in each microarray spot. Vessel density was measured by vWF staining. Significance was determined using the Chi square test for each GEM to compare normal versus metastatic tumor (M) and normal versus glioblastoma (G) at a level <0.05. No markers were able to discriminate normal versus pilocytic tumor or metastatic tumor versus glioblastoma